May 23, 2018 / 10:11 AM / 3 months ago

BRIEF-Cara Therapeutics And Vifor Fresenius Medical Care Renal Pharma Enter Into Ex-U.S. Licensing Agreement

May 23 (Reuters) - Cara Therapeutics Inc:

* CARA THERAPEUTICS AND VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA (VFMCRP) ENTER INTO EX-U.S. LICENSING AGREEMENT TO COMMERCIALIZE KORSUVA™ INJECTION IN DIALYSIS PATIENTS WITH PRURITUS

* CARA THERAPEUTICS INC - CARA ELIGIBLE FOR UP TO $470 MILLION IN REGULATORY AND COMMERCIAL MILESTONES

* CARA THERAPEUTICS INC - VFMCRP TO COMMERCIALIZE KORSUVA INJECTION WORLDWIDE EXCEPT IN U.S., JAPAN AND SOUTH KOREA

* CARA THERAPEUTICS INC - CARA RECEIVES UPFRONT PAYMENT OF $50 MILLION IN CASH AND AN EQUITY INVESTMENT OF $20 MILLION

* CARA THERAPEUTICS INC - CARA IS ELIGIBLE TO RECEIVE TIERED ROYALTIES BASED ON NET SALES OF KORSUVA INJECTION IN LICENSED TERRITORIES

* CARA THERAPEUTICS INC - CARA WILL SOLELY PROMOTE KORSUVA INJECTION IN ALL NON-FMC CLINICS IN U.S. AND RETAIN ALL PROFITS FROM THOSE SALES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below